<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02401230</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00077593</org_study_id>
    <nct_id>NCT02401230</nct_id>
  </id_info>
  <brief_title>PrEP, Lube, and the Rectal Mucosa in MSM at Risk of HIV</brief_title>
  <official_title>Defining the Rectal Mucosa in Men Who Have Sex With Men at Risk of HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the use of rectal lubricants can affect how
      well the medication, Truvada, will work to prevent infection with HIV when someone is exposed
      to HIV in the rectum.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Men who have sex with men (MSM) continue to be disproportionately affected by HIV. The
      majority of HIV infections among MSM occur through exposure to the rectal mucosa during
      receptive anal intercourse (RAI). During RAI, many MSM will use lubricants, which can
      potentially cause mucosal inflammation and damage. A new HIV prevention intervention, called
      pre-exposure prophylaxis (PrEP), recommends that MSM at risk of HIV infection take a daily
      anti-HIV medication called Truvada (tenofovir/emtricitabine) which is highly effective.
      However, it is not known if the use of lubricant during RAI will interfere with the efficacy
      of PrEP for HIV prevention.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Actual">January 25, 2017</completion_date>
  <primary_completion_date type="Actual">January 25, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Percentage of CD4 Positive T-Cells</measure>
    <time_frame>Baseline, Post-Intervention (Day 8)</time_frame>
    <description>HIV target cell availability will be assessed by the median percentage of CD4+ T cells that express HIV co-receptor CCR5 as measured prior to product use and on day 8 after product use.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Cumulative Amount of p24</measure>
    <time_frame>Baseline, Post-Intervention (Day 8)</time_frame>
    <description>The median cumulative amount of p24 produced in a rectal explant challenge assay as measured by ELISA from participants prior to product use and on day 8 after product use.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Plasma Emtricitabine (FTC) Concentration</measure>
    <time_frame>Post-Intervention (Day 8)</time_frame>
    <description>Median plasma FTC concentration as measured in ng/ml prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Plasma Tenofovir (TDF) Concentration</measure>
    <time_frame>Post-Intervention (Day 8)</time_frame>
    <description>Median plasma TDF concentration as measured in ng/ml prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Rectal Secretion Emtricitabine (FTC) Concentration</measure>
    <time_frame>Post-Intervention (Day 8)</time_frame>
    <description>Median rectal secretions FTC concentrations as measured in ng/swab prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Rectal Secretion Tenofovir (TDF) Concentration</measure>
    <time_frame>Post-Intervention (Day 8)</time_frame>
    <description>Median rectal secretions TDF concentrations as measured in ng/swab prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Peripheral Blood Mononuclear Cell (PBMC) Emtricitabine (FTC) Concentration</measure>
    <time_frame>Post-Intervention (Day 8)</time_frame>
    <description>Median blood PBMC FTC concentrations as measured in fmol/million cells prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Peripheral Blood Mononuclear Cell (PBMC) Tenofovir (TDF) Concentration</measure>
    <time_frame>Post-Intervention (Day 8)</time_frame>
    <description>Median blood PBMC TDF concentrations as measured in fmol/million cells prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Rectal Tissue Emtricitabine (FTC) Concentration</measure>
    <time_frame>Post-Intervention (Day 8)</time_frame>
    <description>Median rectal tissue FTC concentrations as measured in fmol/mg tissue prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Rectal Tissue Tenofovir (TDF) Concentration</measure>
    <time_frame>Post-Intervention (Day 8)</time_frame>
    <description>Median rectal tissue TDF concentrations as measured in fmol/mg tissue prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Rectal Tissue Deoxyadenosine Triphosphate (dATP) Concentration</measure>
    <time_frame>Baseline, Post-Intervention (Day 8)</time_frame>
    <description>Median rectal tissue dATP concentrations as measured in fmol/mg tissue prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Rectal Tissue Deoxycytidine Triphosphate (dCTP) Concentration</measure>
    <time_frame>Baseline, Post-Intervention (Day 8)</time_frame>
    <description>Median rectal tissue dCTP concentrations as measured in fmol/mg tissue prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Peripheral Blood Mononuclear Cell (PBMC) Deoxyadenosine Triphosphate (dATP) Concentration</measure>
    <time_frame>Baseline, Post-Intervention (Day 8)</time_frame>
    <description>Median blood dATP concentrations as measured in fmol/million cells prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Rectal Gel Lubricant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will insert 5 mL of lubricant in rectum for seven consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Truvada</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will take one Truvada tablet orally for seven consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rectal Gel Lubricant + Truvada</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will insert 5 mL of lubricant in rectum and take one Truvada tablet orally for seven consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Truvada</intervention_name>
    <description>Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.</description>
    <arm_group_label>Truvada</arm_group_label>
    <arm_group_label>Rectal Gel Lubricant + Truvada</arm_group_label>
    <other_name>Emtricitabine</other_name>
    <other_name>Tenofovir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Gel lubricant</intervention_name>
    <description>Five ml of an over the counter sexual lubricant will be dispensed using an applicator.</description>
    <arm_group_label>Rectal Gel Lubricant</arm_group_label>
    <arm_group_label>Rectal Gel Lubricant + Truvada</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-negative man who reports receptive anal sex with another man in the last 6 months
             aged 18-49 years

          -  Male to female transgender women who are not currently taking hormonal therapy or plan
             to take hormonal therapy for the duration of the study

          -  Not currently taking pre-exposure prophylaxis (PrEP) and no plans to initiate during
             study

          -  Able to provide informed consent in English

          -  No plans for relocation in the next 6 months

          -  Willing to undergo peripheral blood and rectal biopsy sampling

          -  Willing to use study products as directed

          -  Willing to abstain from receptive anal intercourse 3 days prior to study visit 2 (4-16
             weeks after the screening visit)and 10 days prior to study visit 4 (5-26 weeks after
             the screening visit)

          -  Willing to abstain from receptive anal intercourse for 1 week after study visit 2
             (4-16 weeks after the screening visit) and study visit 4 (5-26 weeks after the
             screening visit)

        Exclusion Criteria:

          -  History of inflammatory bowel disease or other inflammatory, infiltrative, infectious
             or vascular condition involving the lower gastrointestinal tract that, in the judgment
             of the investigators, may be worsened by study procedures or may significantly distort
             the anatomy of the distal large bowel

          -  Significant laboratory abnormalities at baseline visit for rectal biopsies, including
             but not limited to:

               1. Hemoglobin (Hbg) â‰¤ 10 g/dL

               2. Partial thromboplastin time (PTT) &gt; 1.5x upper limit normal (ULN) or
                  international normalized ratio (INR) &gt; 1.5x ULN

               3. Platelet count &lt;100,000

          -  Any known medical condition that, in the judgment of the investigators, increases the
             risk of local or systemic complications of endoscopic procedures or pelvic
             examination, including but not limited to:

               1. Uncontrolled or severe cardiac arrhythmia

               2. Recent major abdominal, cardiothoracic, or neurological surgery

               3. History of uncontrolled bleeding diathesis

               4. History of colonic, rectal, or vaginal perforation, fistula, or malignancy

               5. History or evidence on clinical examination of ulcerative, suppurative, or
                  proliferative lesions of the anorectal or vaginal mucosa, or untreated sexually
                  transmitted disease with mucosal involvement

          -  Continued need for, or use during the 14 days prior to enrollment, of the following
             medications:

               1. Aspirin or more than 4 doses of nonsteroidal anti-inflammatory drugs (NSAIDs)

               2. Warfarin, heparin (low-molecular weight or unfractionated), platelet aggregation
                  inhibitors, or fibrinolytic agents

               3. Any form of rectally administered agent besides products lubricants or douching
                  used for sexual intercourse

          -  Continued need for, or use during the 90 days prior to enrollment, of the following
             medications:

               1. Systemic immunomodulatory agents

               2. Supraphysiologic doses of steroids

               3. Experimental medications, vaccines, or biologicals

          -  Intent to use HIV antiretroviral PrEP during the study, outside of the study
             procedures

          -  Symptoms of an untreated rectal sexually transmitted infection (e.g. rectal pain,
             discharge, bleeding, etc.)

          -  Current use of hormonal therapy

          -  Any other clinical condition or prior therapy that, in the opinion of the
             investigator, would make the patient unsuitable for the study or unable to comply with
             the study requirements
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colleen Kelley, MD/MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Hope Clinic of of Emory University</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2015</study_first_submitted>
  <study_first_submitted_qc>March 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2015</study_first_posted>
  <results_first_submitted>December 19, 2017</results_first_submitted>
  <results_first_submitted_qc>January 22, 2018</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 16, 2018</results_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Colleen Kelley</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Human Immunodeficiency Virus</keyword>
  <keyword>Acquired Immune Deficiency Syndrome Virus</keyword>
  <keyword>Pre-exposure Prophylaxis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited March 2015 through November 2016.</recruitment_details>
      <pre_assignment_details>Of the 86 subjects consented for study participation, 76 were randomized to a study intervention.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Rectal Gel Lubricant</title>
          <description>Subjects inserted 5 mL of lubricant in rectum for seven consecutive days.
Gel lubricant: Five ml of an over the counter sexual lubricant will be dispensed using an applicator.</description>
        </group>
        <group group_id="P2">
          <title>Truvada</title>
          <description>Subjects took one Truvada tablet orally for seven consecutive days.
Truvada: Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.</description>
        </group>
        <group group_id="P3">
          <title>Rectal Gel Lubricant + Truvada</title>
          <description>Subjects inserted 5 mL of lubricant in rectum and took one Truvada tablet orally for seven consecutive days
Truvada: Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.
Gel lubricant: Five ml of an over the counter sexual lubricant will be dispensed using an applicator.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants who began a study intervention and completed all study visits.</population>
      <group_list>
        <group group_id="B1">
          <title>Rectal Gel Lubricant</title>
          <description>Subjects inserted 5 mL of lubricant in rectum for seven consecutive days
Gel lubricant: Five ml of an over the counter sexual lubricant will be dispensed using an applicator.</description>
        </group>
        <group group_id="B2">
          <title>Truvada</title>
          <description>Subjects took one Truvada tablet orally for seven consecutive days
Truvada: Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.</description>
        </group>
        <group group_id="B3">
          <title>Rectal Gel Lubricant + Truvada</title>
          <description>Subjects inserted 5 mL of lubricant in rectum and took one Truvada tablet orally for seven consecutive days
Truvada: Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.
Gel lubricant: Five ml of an over the counter sexual lubricant will be dispensed using an applicator.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="21"/>
            <count group_id="B4" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="21"/>
                    <count group_id="B4" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="21"/>
                    <count group_id="B4" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="21"/>
                    <count group_id="B4" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Percentage of CD4 Positive T-Cells</title>
        <description>HIV target cell availability will be assessed by the median percentage of CD4+ T cells that express HIV co-receptor CCR5 as measured prior to product use and on day 8 after product use.</description>
        <time_frame>Baseline, Post-Intervention (Day 8)</time_frame>
        <population>The analysis population includes participants for whom the assay could be accurately performed. Data were not available for analysis in the case of an insufficient sample to perform this assay, poor performance of the assay, or technical issues in the laboratory.</population>
        <group_list>
          <group group_id="O1">
            <title>Rectal Gel Lubricant</title>
            <description>Subjects inserted 5 mL of lubricant in rectum for seven consecutive days.
Gel lubricant: Five ml of an over the counter sexual lubricant will be dispensed using an applicator.</description>
          </group>
          <group group_id="O2">
            <title>Truvada</title>
            <description>Subjects took one Truvada tablet orally for seven consecutive days.
Truvada: Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.</description>
          </group>
          <group group_id="O3">
            <title>Rectal Gel Lubricant + Truvada</title>
            <description>Subjects inserted 5 mL of lubricant in rectum and took one Truvada tablet orally for seven consecutive days
Truvada: Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.
Gel lubricant: Five ml of an over the counter sexual lubricant will be dispensed using an applicator.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Percentage of CD4 Positive T-Cells</title>
          <description>HIV target cell availability will be assessed by the median percentage of CD4+ T cells that express HIV co-receptor CCR5 as measured prior to product use and on day 8 after product use.</description>
          <population>The analysis population includes participants for whom the assay could be accurately performed. Data were not available for analysis in the case of an insufficient sample to perform this assay, poor performance of the assay, or technical issues in the laboratory.</population>
          <units>percentage positive T-cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" lower_limit="50" upper_limit="70"/>
                    <measurement group_id="O2" value="70" lower_limit="39" upper_limit="76"/>
                    <measurement group_id="O3" value="58" lower_limit="32" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66" lower_limit="29" upper_limit="72"/>
                    <measurement group_id="O2" value="58" lower_limit="39" upper_limit="71"/>
                    <measurement group_id="O3" value="51" lower_limit="14" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Cumulative Amount of p24</title>
        <description>The median cumulative amount of p24 produced in a rectal explant challenge assay as measured by ELISA from participants prior to product use and on day 8 after product use.</description>
        <time_frame>Baseline, Post-Intervention (Day 8)</time_frame>
        <population>Number of participants who provided a viable sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Rectal Gel Lubricant</title>
            <description>Subjects inserted 5 mL of lubricant in rectum for seven consecutive days
Gel lubricant: Five ml of an over the counter sexual lubricant will be dispensed using an applicator.</description>
          </group>
          <group group_id="O2">
            <title>Truvada</title>
            <description>Subjects took one Truvada tablet orally for seven consecutive days
Truvada: Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.</description>
          </group>
          <group group_id="O3">
            <title>Rectal Gel Lubricant + Truvada</title>
            <description>Subjects inserted 5 mL of lubricant in rectum and took one Truvada tablet orally for seven consecutive days
Truvada: Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.
Gel lubricant: Five ml of an over the counter sexual lubricant will be dispensed using an applicator.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Cumulative Amount of p24</title>
          <description>The median cumulative amount of p24 produced in a rectal explant challenge assay as measured by ELISA from participants prior to product use and on day 8 after product use.</description>
          <population>Number of participants who provided a viable sample.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250" lower_limit="138" upper_limit="608"/>
                    <measurement group_id="O2" value="287" lower_limit="80" upper_limit="944"/>
                    <measurement group_id="O3" value="276" lower_limit="82" upper_limit="786"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="363" lower_limit="102" upper_limit="494"/>
                    <measurement group_id="O2" value="133" lower_limit="68" upper_limit="363"/>
                    <measurement group_id="O3" value="284" lower_limit="114" upper_limit="369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Plasma Emtricitabine (FTC) Concentration</title>
        <description>Median plasma FTC concentration as measured in ng/ml prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.</description>
        <time_frame>Post-Intervention (Day 8)</time_frame>
        <population>Number of participants who provided a viable sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Subjects took one Truvada tablet orally for seven consecutive days
Truvada: Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.</description>
          </group>
          <group group_id="O2">
            <title>Rectal Gel Lubricant + Truvada</title>
            <description>Subjects inserted 5 mL of lubricant in rectum and took one Truvada tablet orally for seven consecutive days
Truvada: Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.
Gel lubricant: Five ml of an over the counter sexual lubricant will be dispensed using an applicator.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Plasma Emtricitabine (FTC) Concentration</title>
          <description>Median plasma FTC concentration as measured in ng/ml prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.</description>
          <population>Number of participants who provided a viable sample.</population>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="248" lower_limit="71" upper_limit="277"/>
                    <measurement group_id="O2" value="340" lower_limit="8" upper_limit="509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Plasma Tenofovir (TDF) Concentration</title>
        <description>Median plasma TDF concentration as measured in ng/ml prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.</description>
        <time_frame>Post-Intervention (Day 8)</time_frame>
        <population>Number of participants who provided a viable sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Subjects took one Truvada tablet orally for seven consecutive days
Truvada: Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.</description>
          </group>
          <group group_id="O2">
            <title>Rectal Gel Lubricant + Truvada</title>
            <description>Subjects inserted 5 mL of lubricant in rectum and took one Truvada tablet orally for seven consecutive days
Truvada: Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.
Gel lubricant: Five ml of an over the counter sexual lubricant will be dispensed using an applicator.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Plasma Tenofovir (TDF) Concentration</title>
          <description>Median plasma TDF concentration as measured in ng/ml prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.</description>
          <population>Number of participants who provided a viable sample.</population>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" lower_limit="27" upper_limit="73"/>
                    <measurement group_id="O2" value="64" lower_limit="17" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Rectal Secretion Emtricitabine (FTC) Concentration</title>
        <description>Median rectal secretions FTC concentrations as measured in ng/swab prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.</description>
        <time_frame>Post-Intervention (Day 8)</time_frame>
        <population>Number of participants who provided a viable sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Subjects took one Truvada tablet orally for seven consecutive days
Truvada: Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.</description>
          </group>
          <group group_id="O2">
            <title>Rectal Gel Lubricant + Truvada</title>
            <description>Subjects inserted 5 mL of lubricant in rectum and took one Truvada tablet orally for seven consecutive days
Truvada: Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.
Gel lubricant: Five ml of an over the counter sexual lubricant will be dispensed using an applicator.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Rectal Secretion Emtricitabine (FTC) Concentration</title>
          <description>Median rectal secretions FTC concentrations as measured in ng/swab prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.</description>
          <population>Number of participants who provided a viable sample.</population>
          <units>ng/swab</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="320" lower_limit="43" upper_limit="661"/>
                    <measurement group_id="O2" value="382" lower_limit="38" upper_limit="570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Rectal Secretion Tenofovir (TDF) Concentration</title>
        <description>Median rectal secretions TDF concentrations as measured in ng/swab prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.</description>
        <time_frame>Post-Intervention (Day 8)</time_frame>
        <population>Number of participants who provided a viable sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Subjects took one Truvada tablet orally for seven consecutive days
Truvada: Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.</description>
          </group>
          <group group_id="O2">
            <title>Rectal Gel Lubricant + Truvada</title>
            <description>Subjects inserted 5 mL of lubricant in rectum and took one Truvada tablet orally for seven consecutive days
Truvada: Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.
Gel lubricant: Five ml of an over the counter sexual lubricant will be dispensed using an applicator.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Rectal Secretion Tenofovir (TDF) Concentration</title>
          <description>Median rectal secretions TDF concentrations as measured in ng/swab prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.</description>
          <population>Number of participants who provided a viable sample.</population>
          <units>ng/swab</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="812" lower_limit="170" upper_limit="1535"/>
                    <measurement group_id="O2" value="780" lower_limit="61" upper_limit="3160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Peripheral Blood Mononuclear Cell (PBMC) Emtricitabine (FTC) Concentration</title>
        <description>Median blood PBMC FTC concentrations as measured in fmol/million cells prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.</description>
        <time_frame>Post-Intervention (Day 8)</time_frame>
        <population>Number of participants who provided a viable sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Subjects took one Truvada tablet orally for seven consecutive days
Truvada: Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.</description>
          </group>
          <group group_id="O2">
            <title>Rectal Gel Lubricant + Truvada</title>
            <description>Subjects inserted 5 mL of lubricant in rectum and took one Truvada tablet orally for seven consecutive days
Truvada: Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.
Gel lubricant: Five ml of an over the counter sexual lubricant will be dispensed using an applicator.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Peripheral Blood Mononuclear Cell (PBMC) Emtricitabine (FTC) Concentration</title>
          <description>Median blood PBMC FTC concentrations as measured in fmol/million cells prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.</description>
          <population>Number of participants who provided a viable sample.</population>
          <units>fmol/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4980" lower_limit="1554" upper_limit="5730"/>
                    <measurement group_id="O2" value="4020" lower_limit="1399" upper_limit="5370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Peripheral Blood Mononuclear Cell (PBMC) Tenofovir (TDF) Concentration</title>
        <description>Median blood PBMC TDF concentrations as measured in fmol/million cells prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.</description>
        <time_frame>Post-Intervention (Day 8)</time_frame>
        <population>Number of participants who provided a viable sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Subjects took one Truvada tablet orally for seven consecutive days
Truvada: Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.</description>
          </group>
          <group group_id="O2">
            <title>Rectal Gel Lubricant + Truvada</title>
            <description>Subjects inserted 5 mL of lubricant in rectum and took one Truvada tablet orally for seven consecutive days
Truvada: Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.
Gel lubricant: Five ml of an over the counter sexual lubricant will be dispensed using an applicator.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Peripheral Blood Mononuclear Cell (PBMC) Tenofovir (TDF) Concentration</title>
          <description>Median blood PBMC TDF concentrations as measured in fmol/million cells prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.</description>
          <population>Number of participants who provided a viable sample.</population>
          <units>fmol/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" lower_limit="25" upper_limit="57"/>
                    <measurement group_id="O2" value="48" lower_limit="24" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Rectal Tissue Emtricitabine (FTC) Concentration</title>
        <description>Median rectal tissue FTC concentrations as measured in fmol/mg tissue prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.</description>
        <time_frame>Post-Intervention (Day 8)</time_frame>
        <population>Number of participants who provided a viable sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Subjects took one Truvada tablet orally for seven consecutive days
Truvada: Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.</description>
          </group>
          <group group_id="O2">
            <title>Rectal Gel Lubricant + Truvada</title>
            <description>Subjects inserted 5 mL of lubricant in rectum and took one Truvada tablet orally for seven consecutive days
Truvada: Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.
Gel lubricant: Five ml of an over the counter sexual lubricant will be dispensed using an applicator.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Rectal Tissue Emtricitabine (FTC) Concentration</title>
          <description>Median rectal tissue FTC concentrations as measured in fmol/mg tissue prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.</description>
          <population>Number of participants who provided a viable sample.</population>
          <units>fmol/mg tissue</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104" lower_limit="4" upper_limit="203"/>
                    <measurement group_id="O2" value="112" lower_limit="16" upper_limit="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Rectal Tissue Tenofovir (TDF) Concentration</title>
        <description>Median rectal tissue TDF concentrations as measured in fmol/mg tissue prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.</description>
        <time_frame>Post-Intervention (Day 8)</time_frame>
        <population>Number of participants who provided a viable sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Subjects took one Truvada tablet orally for seven consecutive days
Truvada: Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.</description>
          </group>
          <group group_id="O2">
            <title>Rectal Gel Lubricant + Truvada</title>
            <description>Subjects inserted 5 mL of lubricant in rectum and took one Truvada tablet orally for seven consecutive days
Truvada: Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.
Gel lubricant: Five ml of an over the counter sexual lubricant will be dispensed using an applicator.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Rectal Tissue Tenofovir (TDF) Concentration</title>
          <description>Median rectal tissue TDF concentrations as measured in fmol/mg tissue prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.</description>
          <population>Number of participants who provided a viable sample.</population>
          <units>fmol/mg tissue</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="510" lower_limit="4" upper_limit="1191"/>
                    <measurement group_id="O2" value="280" lower_limit="19" upper_limit="561"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Rectal Tissue Deoxyadenosine Triphosphate (dATP) Concentration</title>
        <description>Median rectal tissue dATP concentrations as measured in fmol/mg tissue prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.</description>
        <time_frame>Baseline, Post-Intervention (Day 8)</time_frame>
        <population>Number of participants who provided a viable sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Subjects took one Truvada tablet orally for seven consecutive days
Truvada: Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.</description>
          </group>
          <group group_id="O2">
            <title>Rectal Gel Lubricant + Truvada</title>
            <description>Subjects inserted 5 mL of lubricant in rectum and took one Truvada tablet orally for seven consecutive days
Truvada: Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.
Gel lubricant: Five ml of an over the counter sexual lubricant will be dispensed using an applicator.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Rectal Tissue Deoxyadenosine Triphosphate (dATP) Concentration</title>
          <description>Median rectal tissue dATP concentrations as measured in fmol/mg tissue prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.</description>
          <population>Number of participants who provided a viable sample.</population>
          <units>fmol/mg tissue</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131" lower_limit="12" upper_limit="262"/>
                    <measurement group_id="O2" value="74" lower_limit="19" upper_limit="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Intervention (Day 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="14" upper_limit="155"/>
                    <measurement group_id="O2" value="66" lower_limit="19" upper_limit="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Rectal Tissue Deoxycytidine Triphosphate (dCTP) Concentration</title>
        <description>Median rectal tissue dCTP concentrations as measured in fmol/mg tissue prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.</description>
        <time_frame>Baseline, Post-Intervention (Day 8)</time_frame>
        <population>Number of participants who provided a viable sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Subjects took one Truvada tablet orally for seven consecutive days
Truvada: Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.</description>
          </group>
          <group group_id="O2">
            <title>Rectal Gel Lubricant + Truvada</title>
            <description>Subjects inserted 5 mL of lubricant in rectum and took one Truvada tablet orally for seven consecutive days
Truvada: Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.
Gel lubricant: Five ml of an over the counter sexual lubricant will be dispensed using an applicator.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Rectal Tissue Deoxycytidine Triphosphate (dCTP) Concentration</title>
          <description>Median rectal tissue dCTP concentrations as measured in fmol/mg tissue prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.</description>
          <population>Number of participants who provided a viable sample.</population>
          <units>fmol/mg tissue</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="246" lower_limit="7" upper_limit="414"/>
                    <measurement group_id="O2" value="58" lower_limit="10" upper_limit="395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Intervention (Day 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" lower_limit="6" upper_limit="131"/>
                    <measurement group_id="O2" value="36" lower_limit="11" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Peripheral Blood Mononuclear Cell (PBMC) Deoxyadenosine Triphosphate (dATP) Concentration</title>
        <description>Median blood dATP concentrations as measured in fmol/million cells prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.</description>
        <time_frame>Baseline, Post-Intervention (Day 8)</time_frame>
        <population>Number of participants who provided a viable sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Truvada</title>
            <description>Subjects took one Truvada tablet orally for seven consecutive days
Truvada: Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.</description>
          </group>
          <group group_id="O2">
            <title>Rectal Gel Lubricant + Truvada</title>
            <description>Subjects inserted 5 mL of lubricant in rectum and took one Truvada tablet orally for seven consecutive days
Truvada: Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.
Gel lubricant: Five ml of an over the counter sexual lubricant will be dispensed using an applicator.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Peripheral Blood Mononuclear Cell (PBMC) Deoxyadenosine Triphosphate (dATP) Concentration</title>
          <description>Median blood dATP concentrations as measured in fmol/million cells prior to product use and on day 8 after product use. The higher the concentration, the better the drug distribution.</description>
          <population>Number of participants who provided a viable sample.</population>
          <units>fmol/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149" lower_limit="16" upper_limit="187"/>
                    <measurement group_id="O2" value="140" lower_limit="25" upper_limit="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Intervention (Day 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204" lower_limit="56" upper_limit="269"/>
                    <measurement group_id="O2" value="122" lower_limit="35" upper_limit="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected throughout study duration (1 year and 7 months).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Rectal Gel Lubricant</title>
          <description>Subjects inserted 5 mL of lubricant in rectum for seven consecutive days.
Gel lubricant: Five ml of an over the counter sexual lubricant will be dispensed using an applicator.</description>
        </group>
        <group group_id="E2">
          <title>Truvada</title>
          <description>Subjects took one Truvada tablet orally for seven consecutive days.
Truvada: Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.</description>
        </group>
        <group group_id="E3">
          <title>Rectal Gel Lubricant + Truvada</title>
          <description>Subjects inserted 5 mL of lubricant in rectum and took one Truvada tablet orally for seven consecutive days
Truvada: Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.
Gel lubricant: Five ml of an over the counter sexual lubricant will be dispensed using an applicator.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile Dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Colleen Kelley</name_or_title>
      <organization>Emory University</organization>
      <phone>404-712-1823</phone>
      <email>colleen.kelley@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

